title: Advances in autosomal dominant polycystic kidney disease-2014 and beyond.
abstract: Autosomal dominant polycystic kidney disease (ADPKD), which frequently leads to end-stage renal disease, currently has no specific drug therapies. Better understanding of its pathogenesis and recent clinical trials have led to more accurate diagnosis of the disease and its manifestations, as well as to promising new approaches to treatment.
authors.affiliation: Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, one of seven US centers participating in the HALT-PKD collaborative study braunw@ccf.org.
authors.forename: William E
authors.initials: WE
authors.lastname: Braun
mesh_terms: D055808:Drug Discovery; D006801:Humans; D006973:Hypertension / Q000209:etiology; D002532:Intracranial Aneurysm / Q000209:etiology; D010146:Pain / Q000209:etiology; D016891:Polycystic Kidney, Autosomal Dominant / Q000150:complications / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D014552:Urinary Tract Infections / Q000209:etiology; D014667:Vasopressins / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D014667:Vasopressins; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases